Pegvisomant vs Sermorelin
Research Verdict
Pegvisomant is the stronger research reference for the stated comparison criteria. Pegvisomant (Somavert): FDA approved for acromegaly, Phase 3 data showing IGF-1 normalization in ~90% of patients (Trainer et al.
Quick Answers
Which is better, Pegvisomant or Sermorelin?
Pegvisomant is the stronger research reference for the stated comparison criteria. Pegvisomant (Somavert): FDA approved for acromegaly, Phase 3 data showing IGF-1 normalization in ~90% of patients (Trainer et al.
What is the key difference between Pegvisomant and Sermorelin?
These are pharmacological opposites - pegvisomant is a GH receptor antagonist that lowers IGF-1; sermorelin is a GHRH analog that raises GH and IGF-1. They cannot substitute for each other.
Evidence Comparison
Pegvisomant (Somavert): FDA approved for acromegaly, Phase 3 data showing IGF-1 normalization in ~90% of patients (Trainer et al. 2000, NEJM). Sermorelin: FDA approved for GH deficiency (withdrawn commercially 2008), 6-month RCT in elderly adults. Both have human trial data; pegvisomant has the more robust modern evidence base.
Evidence Context Favoring Pegvisomant
GH receptor blockade in acromegaly or research into GH excess states - pegvisomant is the FDA-approved standard.
Evidence Context Favoring Sermorelin
GH stimulation testing or research into GH deficiency where physiological GH pulsatility enhancement is the goal.
Side-by-Side Snapshot
| Evidence grade | Pegvisomant: Level A Sermorelin: Level B |
|---|---|
| Research status | Pegvisomant: FDA Approved Sermorelin: Historical FDA Approval |
| Primary category | Pegvisomant: Growth Hormone Sermorelin: Growth Hormone |
| Cited studies | Pegvisomant: 2 Sermorelin: 2 |